Vanguard Capital Management’s Scribe Therapeutics SCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding SCTX
BBA
Vanguard Capital Management's SCTX Position: Q3 2026 in Review
Vanguard Capital Management opened a new position in Scribe Therapeutics (SCTX) in Q3 2026: 407,630 shares worth $7.5M. The stake represents ﹤0.01% of the portfolio and ranks #2928 among its holdings.
63 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.
- Vanguard Capital Management held 407,630 shares of Scribe Therapeutics worth $7.5M as of Q3 2026.
- Scribe Therapeutics was a new Vanguard Capital Management position in Q3 2026.
- Scribe Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2928 holding.
- 63 funds tracked by Wall St. Rank held Scribe Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.